The start of Phase I trials for MTX102, a first-in-man diabetes immunotherapy using Midatech’s proprietary gold nanoparticle technology, is encouraging. The programme aims to reduce the immune response that causes destruction of insulin producing cells in the pancreas in Type 1 diabetes patients, which represents a potential novel treatment paradigm. We look forward to results in 2017 with anticipation.
30 Sep 2016
N+1 Singer - Midatech Pharma - Diabetes immunotherapy MTX102 enters Phase I trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Midatech Pharma - Diabetes immunotherapy MTX102 enters Phase I trial
- Published:
30 Sep 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The start of Phase I trials for MTX102, a first-in-man diabetes immunotherapy using Midatech’s proprietary gold nanoparticle technology, is encouraging. The programme aims to reduce the immune response that causes destruction of insulin producing cells in the pancreas in Type 1 diabetes patients, which represents a potential novel treatment paradigm. We look forward to results in 2017 with anticipation.